RU2261723C2 - Молчащие анти-cd28-антитела и их применение - Google Patents

Молчащие анти-cd28-антитела и их применение Download PDF

Info

Publication number
RU2261723C2
RU2261723C2 RU2003121231/15A RU2003121231A RU2261723C2 RU 2261723 C2 RU2261723 C2 RU 2261723C2 RU 2003121231/15 A RU2003121231/15 A RU 2003121231/15A RU 2003121231 A RU2003121231 A RU 2003121231A RU 2261723 C2 RU2261723 C2 RU 2261723C2
Authority
RU
Russia
Prior art keywords
antibodies
antibody
cells
seq
igg3
Prior art date
Application number
RU2003121231/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2003121231A (ru
Inventor
Дз. Юн ЦО (US)
Дз. Юн ЦО
Пол ХИНТОН (US)
Пол ХИНТОН
Максимиль но ВАСКЕС (US)
Максимильяно Васкес
Коуити ТАМУРА (JP)
Коуити ТАМУРА
Ясуюки ХИГАСИ (JP)
Ясуюки Хигаси
Нобуо СЕКИ (JP)
Нобуо СЕКИ
Хироцугу УЕДА (JP)
Хироцугу УЕДА
Original Assignee
Фудзисава Фармасьютикал Ко.,Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фудзисава Фармасьютикал Ко.,Лтд. filed Critical Фудзисава Фармасьютикал Ко.,Лтд.
Publication of RU2003121231A publication Critical patent/RU2003121231A/ru
Application granted granted Critical
Publication of RU2261723C2 publication Critical patent/RU2261723C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2003121231/15A 2000-12-14 2001-12-14 Молчащие анти-cd28-антитела и их применение RU2261723C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
US60/255,155 2000-12-14

Publications (2)

Publication Number Publication Date
RU2003121231A RU2003121231A (ru) 2005-02-10
RU2261723C2 true RU2261723C2 (ru) 2005-10-10

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003121231/15A RU2261723C2 (ru) 2000-12-14 2001-12-14 Молчащие анти-cd28-антитела и их применение

Country Status (18)

Country Link
EP (1) EP1341553A4 (ko)
JP (1) JP2004515243A (ko)
KR (1) KR20040020866A (ko)
CN (1) CN1272345C (ko)
AR (1) AR031924A1 (ko)
AU (2) AU2002226086C1 (ko)
BR (1) BR0116686A (ko)
CA (1) CA2432736A1 (ko)
CZ (1) CZ20031909A3 (ko)
HU (1) HUP0400697A3 (ko)
IL (1) IL156262A0 (ko)
MX (1) MXPA03005327A (ko)
NO (1) NO20032542L (ko)
NZ (1) NZ526569A (ko)
PL (1) PL363239A1 (ko)
RU (1) RU2261723C2 (ko)
WO (1) WO2002047721A1 (ko)
ZA (1) ZA200305384B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
FR2951176A1 (fr) 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
CA2788544C (en) * 2010-02-18 2019-03-05 Effimune Anti-cd28 humanized antibodies
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020183471A1 (en) * 2019-03-14 2020-09-17 Biond Biologics Ltd. A method for immunosuppression
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAN et al, «Humanization of an Anti-CD28 Antibody...» 2000, v.96, № 11, p.31A. *

Also Published As

Publication number Publication date
CN1272345C (zh) 2006-08-30
AU2608602A (en) 2002-06-24
AU2002226086C1 (en) 2006-03-09
BR0116686A (pt) 2003-12-30
EP1341553A1 (en) 2003-09-10
IL156262A0 (en) 2004-01-04
AU2002226086B2 (en) 2005-08-25
EP1341553A4 (en) 2004-07-28
RU2003121231A (ru) 2005-02-10
AR031924A1 (es) 2003-10-08
ZA200305384B (en) 2004-10-11
WO2002047721A1 (en) 2002-06-20
HUP0400697A2 (hu) 2004-06-28
MXPA03005327A (es) 2004-12-03
NO20032542L (no) 2003-08-07
KR20040020866A (ko) 2004-03-09
JP2004515243A (ja) 2004-05-27
CZ20031909A3 (cs) 2003-11-12
PL363239A1 (en) 2004-11-15
CA2432736A1 (en) 2002-06-20
HUP0400697A3 (en) 2007-05-02
CN1489473A (zh) 2004-04-14
NO20032542D0 (no) 2003-06-05
NZ526569A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
US6887673B2 (en) Humanized antibodies against human 4-1BB
EP0812333B1 (en) Bispecific antibody effective to treat b-cell lymphoma and cell line
RU2261723C2 (ru) Молчащие анти-cd28-антитела и их применение
EP3299392B1 (en) Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates
KR20170057298A (ko) Cd19에 특이적인 항체 및 키메라 항원 수용체
WO1996032495A1 (en) Monoclonal antibody specific for human 4-1bb and cell line producing same
EP3851455B1 (en) Monoclonal antibody specifically binding human and monkey cd38 antigens, preparation method and use thereof
US5951983A (en) Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
CZ287347B6 (en) Humanized antibody, process of its preparation, its use and pharmaceutical preparations based thereon
JP2002506420A (ja) 変異した不活化ＩｇＧ２ドメインおよびこれを組み込んだ抗ＣＤ３抗体
KR19990022650A (ko) 사람 ｂ7.1 및/또는 ｂ7.2 영장류화된 형태에 특이적인 원숭이 단일클론성 항체 및 이의 약제학적 조성물
AU754185B2 (en) LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
JP4448906B2 (ja) Ｃｄ４特異的抗体ｔｒｘ１およびその使用
JP7384835B2 (ja) Ｃｄ３に特異的な抗体及びその使用
CN106939049A (zh) 拮抗抑制人pd‑1抗原与其配体结合的单克隆抗体及其制备方法与应用
MXPA01008098A (es) Inmunoglobulina humanizada reactiva con moleculas b7 y metodo de tratamiento con el mismo.
AU2002226086A1 (en) Silensed anti-CD28 antibodies and use thereof
US20230203178A1 (en) Chimeric antigen receptor car or car construct targeting bcma and cd19 and application thereof
KR20180131989A (ko) 신규한 항-ｃｄ40 항체 및 이의 용도
US20040116675A1 (en) Silenced anti-cd28 antibodies and use thereof
CN116854820B (zh) Pd-1非阻断性清除抗体及其用途
JP7278623B2 (ja) 抗ｃｄ２７抗体およびその使用

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20061215